Literature DB >> 34006554

Impact of the COVID-19 pandemic and related control measures on cancer diagnosis in Catalonia: a time-series analysis of primary care electronic health records covering about five million people.

Ermengol Coma1, Carolina Guiriguet2,3, Nuria Mora2,4, Mercè Marzo-Castillejo4,5, Mencia Benítez2,3, Leonardo Méndez-Boo2, Francesc Fina2, Mireia Fàbregas2, Albert Mercadé2, Manuel Medina2.   

Abstract

OBJECTIVE: Cancer care has been disrupted by the response of health systems to the COVID-19 pandemic, especially during lockdowns. The objective of our study is to evaluate the impact of the pandemic on the incidence of cancer diagnoses in primary care.
DESIGN: Time-series study of malignant neoplasms and diagnostic procedures, using data from the primary care electronic health records from January 2014 to September 2020.
SETTING: Primary care, Catalonia, Spain. PARTICIPANTS: People older than 14 years and assigned in one of the primary care practices of the Catalan Institute of Health with a new diagnosis of malignant neoplasm. MAIN OUTCOME MEASURES: We obtained the monthly expected incidence of malignant neoplasms using a temporary regression, where the response variable was the incidence of cancer from 2014 to 2018 and the adjustment variables were the trend and seasonality of the time series. Excess or lack of malignant neoplasms was defined as the number of observed minus expected cases, globally and stratified by sex, age, type of cancer and socioeconomic status.
RESULTS: Between March and September 2020 we observed 8766 (95% CI 4135 to 13 397) fewer malignant neoplasm diagnoses, representing a reduction of 34% (95% CI 19.5% to 44.1%) compared with the expected. This underdiagnosis was greater in individuals aged older than 64 years, men and in some types of cancers (skin, colorectal, prostate). Although the reduction was predominantly focused during the lockdown, expected figures have not yet been reached (40.5% reduction during the lockdown and 24.3% reduction after that).
CONCLUSIONS: Reduction in cancer incidence has been observed during and after the lockdown. Urgent policy interventions are necessary to mitigate the indirect effects of the COVID-19 pandemic and related control measures on other diseases and some strategies must be designed in order to reduce the underdiagnosis of cancer. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  COVID-19; epidemiology; primary care

Year:  2021        PMID: 34006554     DOI: 10.1136/bmjopen-2020-047567

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


  18 in total

1.  [Accessibility and Digital Divide, the 2.0 Inverse Care Law].

Authors:  Esther Díaz Salcedo; Josep Vidal Alaball
Journal:  Aten Primaria       Date:  2022-10       Impact factor: 2.206

2.  Impact of COVID-19 in Cervical and Breast Cancer Screening and Systemic Treatment in São Paulo, Brazil: An Interrupted Time Series Analysis.

Authors:  Mateus B O Duarte; Juliana L P Argenton; José B C Carvalheira
Journal:  JCO Glob Oncol       Date:  2022-06

3.  Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study.

Authors:  Richard Lee-Ying; Dylan E O'Sullivan; Richard Gagnon; Nicholas Bosma; Rebecca N Stewart; Cindy Railton; Derek Tilley; Nimira Alimohamed; Naveen Basappa; Tina Cheng; Michael Kolinsky; Safiya Karim; Dean Ruether; Scott North; Steven Yip; Brita Danielson; Daniel Heng; Darren Brenner
Journal:  CMAJ Open       Date:  2022-07-05

4.  Delayed Diagnosis and Treatment of Cancer Patients During the COVID-19 Pandemic in Henan, China: An Interrupted Time Series Analysis.

Authors:  Changpeng Liu; Heng Piao; Tao Zhang; Dongjian Yang; Xiaoyan Li; Xiance Tang
Journal:  Front Public Health       Date:  2022-05-24

5.  The impact of the COVID-19 pandemic on cancer diagnosis based on pathology notifications: A comparison across the Nordic countries during 2020.

Authors:  Anna L V Johansson; Siri Larønningen; Charlotte Wessel Skovlund; Marnar Fríðheim Kristiansen; Lina Steinrud Mørch; Søren Friis; Tom Børge Johannesen; Tor Åge Myklebust; Anna Skog; David Pettersson; Helgi Birgisson; Anni Virtanen; Nea Malila; Janne Pitkäniemi; Tomas Tanskanen; Laufey Tryggvadóttir; Giske Ursin; Mats Lambe
Journal:  Int J Cancer       Date:  2022-04-25       Impact factor: 7.316

6.  [Impact of the COVID-19 pandemic on patient-reported patient safety in Primary Care].

Authors:  Maria A Fiol-deRoque; Maria J Serrano-Ripol; Montserrat Gens-Barberà; Encarna Sánchez; Miguel A Mayer; Francisco Martín-Luján; José M Valderas; Ignacio Ricci-Cabello
Journal:  Aten Primaria       Date:  2021-12       Impact factor: 1.137

7.  Delays in Cancer Diagnostic Testing at a Quick Referral Unit in Spain during COVID-19.

Authors:  Xavier Bosch; Manuel Torres; Pedro Moreno; Alfonso López-Soto
Journal:  Diagnostics (Basel)       Date:  2021-11-12

8.  [Primary care organization in pandemic times].

Authors:  Txema Coll Benejam; Jesús Palacio Lapuente; Rosa Añel Rodríguez; Montse Gens Barbera; Juan José Jurado Balbuena; Aina Perelló Bratescu
Journal:  Aten Primaria       Date:  2021-11-19       Impact factor: 1.137

9.  Differences in the Impact of COVID-19 on Pathology Laboratories and Cancer Diagnosis in Girona.

Authors:  Arantza Sanvisens; Montse Puigdemont; Jordi Rubió-Casadevall; Anna Vidal-Vila; Eugeni López-Bonet; Ferran Martín-Romero; Rafael Marcos-Gragera
Journal:  Int J Environ Res Public Health       Date:  2021-12-16       Impact factor: 3.390

10.  Characterization and Identification of Variations in Types of Primary Care Visits Before and During the COVID-19 Pandemic in Catalonia: Big Data Analysis Study.

Authors:  Francesc Lopez Segui; Guillem Hernandez Guillamet; Héctor Pifarré Arolas; Francesc X Marin-Gomez; Anna Ruiz Comellas; Anna Maria Ramirez Morros; Cristina Adroher Mas; Josep Vidal-Alaball
Journal:  J Med Internet Res       Date:  2021-09-14       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.